| abstract |
Provided herein are methods for the treatment of viral infections and inflammation secondary to viral infections (e.g., coronavirus infections (e.g., severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), etc.), etc.) and diseases (e.g., Coronavirus disease 2019 (COVID-19)) associated therewith by the administration of low doses of tocilizumab to a subject. In particular embodiments, provided herein are pharmaceutical compositions comprising doses of 200 mg or less of tocilizumab and methods for the treatment of SARS-CoV-2 infections, COVID-19, inflammation secondary to such infections, and symptoms or other conditions arising as a result thereof. |